Breast Cancer Risk In Postmenopausal Osteoporotic Women Reduced By Lasofoxifene
 

Lasofoxifene statistically reduced the overall risk of breast cancer, as well as ER positive invasive breast cancer in postmenopausal women with low bone density, according to a study published online in The Journal of the National Cancer Institute. Lasofoxifene is a SERM, or selective estrogen receptor modulator, that, like tamoxifen, blocks the effects of estrogen in breast tissue...

More...